Definitive

ALX Resources Corp. Announces Definitive Option Agreement with Trinex Minerals for the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan

Retrieved on: 
Mittwoch, Mai 8, 2024
VWAP, ALX, News, SMG, Share (finance), Legacy, Definitive, CAD, Interest, Letter, Security (finance)

In addition, Trinex Minerals Limited, the parent company of Trinex Canada, has issued 68,743,011 fully paid ordinary shares to ALX representing a value of CAD$250,000 (the "Shares").

Key Points: 
  • In addition, Trinex Minerals Limited, the parent company of Trinex Canada, has issued 68,743,011 fully paid ordinary shares to ALX representing a value of CAD$250,000 (the "Shares").
  • Trinex Canada may withdraw from the Initial Option Interest or Second Option Interest at any time.
  • If Trinex Canada withdraws prior to earning the 51% Project interest, then it will not acquire any interest in the Project.
  • Under the terms of the Definitive Agreement, Trinex Canada will assume operatorship of exploration at Gibbons Creek and will reimburse ALX for the costs of the 2024 program, which totalled approximately CAD$500,000.

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024

Retrieved on: 
Dienstag, Mai 7, 2024
Investment, Health care, Definitive, Growth, Tax, Common stock, Eastern Time Zone, Marketing, Interim, CRM, GAAP, Operation

FRAMINGHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2024.

Key Points: 
  • FRAMINGHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2024.
  • First Quarter 2024 Financial Highlights:
    Revenue was $63.5 million, an increase of 7% from $59.2 million in Q1 2023.
  • “While our first quarter performance was mixed, our adjusted EBITDA margin was strong as we continued to focus on the operational efficiencies,” said Jason Krantz, Founder, Executive Chairman, and Interim CEO of Definitive Healthcare.
  • Definitive Healthcare will host a conference call today May 7, 2024, at 5:00 p.m. (Eastern Time) to discuss the Company's full financial results and current business outlook.

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
Montag, Mai 6, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Education, FDA, CFO, Disorder, Regenerative medicine, University of California, Alexion Pharmaceuticals, PDUFA, Arena Pharmaceuticals, Danon disease, European Medicines Agency, Strategic planning, UCLA, Food, Molecule, Stanford University, Empire, BLA, Medication, Corporate communication, Definitive, Fanconi anemia, Patient, Increment, Safety, Rare disease, Regeneron Pharmaceuticals, AAV, Immunology, EMA, FA, Division, PKD, University, Marketing, MAA, Cell, Biologics license application, Pharmacology, Rare Disease Day, Disease, Mirati Therapeutics, Haematopoietic system, Gene, Society, Pyruvate kinase deficiency, Liberty Science Center, Annual general meeting, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
  • In April, Rocket announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of FA.
  • MAA acceptance was based on positive, previously disclosed data from the global RP-L102 Phase 1/2 clinical trial.
  • Mr. Ondrey was previously the CFO at Mirati Therapeutics and has held multiple senior finance leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.

Bitech Technologies Executes Definitive Agreement with Bridgelink for a Business Combination to Acquire Battery Energy Storage Systems and Solar Projects with estimated capacity of up to 5.8 GW

Retrieved on: 
Montag, April 15, 2024
OTCQB, Solar energy, News, Security (finance), Definitive, Partnership, BESS, Employment, Growth, Business analyst, MIPA, Bank statement, Renewable energy

Emergen controls rights to develop a portfolio of battery energy storage system (“BESS”) projects with a cumulative storage capacity estimated at 1.965 gigawatts (“GW”) and rights to develop a portfolio of solar energy development projects with a cumulative capacity estimated at 3.840 GW (collectively, the “Development Projects”).

Key Points: 
  • Emergen controls rights to develop a portfolio of battery energy storage system (“BESS”) projects with a cumulative storage capacity estimated at 1.965 gigawatts (“GW”) and rights to develop a portfolio of solar energy development projects with a cumulative capacity estimated at 3.840 GW (collectively, the “Development Projects”).
  • The execution of the Definitive Agreement underscores our unified commitment to advancing the Development Projects in the United States including Texas, Arizona, and Louisiana.
  • The Company, under the continued leadership of its current team, will retain its name and ticker symbol while welcoming new executive team members from Bridgelink.
  • “This business combination is a demonstration of a mutually advantageous partnership to benefit our shareholders,” stated Benjamin Tran, CEO of Bitech Technologies.

Bitech Technologies Executes Definitive Agreement with Bridgelink for a Business Combination to Acquire Battery Energy Storage Systems and Solar Projects with estimated capacity of up to 5.8 GW

Retrieved on: 
Montag, April 15, 2024
OTCQB, Solar energy, News, Security (finance), Partnership, Definitive, BESS, Business, Growth, Employment, Business analyst, MIPA, Bank statement, Renewable energy

Emergen controls rights to develop a portfolio of battery energy storage system ("BESS") projects with a cumulative storage capacity estimated at 1.965 gigawatts ("GW") and rights to develop a portfolio of solar energy development projects with a cumulative capacity estimated at 3.840 GW (collectively, the "Development Projects").

Key Points: 
  • Emergen controls rights to develop a portfolio of battery energy storage system ("BESS") projects with a cumulative storage capacity estimated at 1.965 gigawatts ("GW") and rights to develop a portfolio of solar energy development projects with a cumulative capacity estimated at 3.840 GW (collectively, the "Development Projects").
  • The execution of the Definitive Agreement underscores our unified commitment to advancing the Development Projects in the United States including Texas, Arizona, and Louisiana.
  • •         The Company, under the continued leadership of its current team, will retain its name and ticker symbol while welcoming new executive team members from Bridgelink.
  • "This business combination is a demonstration of a mutually advantageous partnership to benefit our shareholders," stated Benjamin Tran, CEO of Bitech Technologies.

Talisker Signs Letter of Intent with Regeneration on Ladner Gold Project Tailings

Retrieved on: 
Donnerstag, April 4, 2024
Engine department, First Nations, TSK, JV, Bralorne, Gold, Metal, University of British Columbia, Rehabilitation, University, Sampling, National instrument, Mineral, Biodiversity, Risk assessment, TSX, Water, Definitive, P80, Uranium mining

TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQX:TSKFF) is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) to form a joint venture with Regeneration Enterprises Inc. (“Regeneration”) to process the Ladner Gold Project (“Ladner”) Tailings Resource (the “Proposed JV”) owned by New Carolin Gold Corp. (“New Carolin”), a 100% owned subsidiary of Talisker.

Key Points: 
  • TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQX:TSKFF) is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) to form a joint venture with Regeneration Enterprises Inc. (“Regeneration”) to process the Ladner Gold Project (“Ladner”) Tailings Resource (the “Proposed JV”) owned by New Carolin Gold Corp. (“New Carolin”), a 100% owned subsidiary of Talisker.
  • Talisker and Regeneration have agreed to share the net profit of the Proposed JV.
  • As a privately held social enterprise, Regeneration identifies and transforms legacy mining sites into ecological assets while producing needed minerals.
  • The business allows for the recovery of significant ounces of gold and complete rehabilitation of the historic tailings facility at Ladner.

Sustainable Green Team, Ltd. (SGTM) Signs Letter-of-Intent Expanding Their Footprint in the Northeast Region

Retrieved on: 
Donnerstag, März 28, 2024
Environment, Partnership, Knowledge, Climate, Lead, Green Team, Food, Technology transfer, OTCQX, LOI, Definitive, Marketing

The agreement calls for an innovative collaboration focused on manufacturing, distribution, and sales of sustainable, eco-friendly products in the Northeast United States.

Key Points: 
  • The agreement calls for an innovative collaboration focused on manufacturing, distribution, and sales of sustainable, eco-friendly products in the Northeast United States.
  • Upon entering into a Definitive Agreement, the partnership aims to revolutionize the region and expects to generate over $50 million in revenue from July 2024 to June 2027.
  • Under the terms of the LOI, Sustainable Green Team, Ltd. will take the lead in manufacturing and technology transfer for groundbreaking products like XLR8®Bio .
  • SGTM and D2E are excited about this sustainable collaboration, which will bring eco-friendly solutions to the Northeast United States.

VML and Definitive Healthcare announce partnership to transform key opinion leader management

Retrieved on: 
Freitag, März 22, 2024
CRM, Partnership, Health, KOL, VML, Definitive, Sales

and LONDON, March 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ) and VML Health announced a first-of-its-kind partnership that gives clients the ability to manage their entire key opinion leader (KOL) identification and engagement operation from an integrated solution.

Key Points: 
  • and LONDON, March 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ) and VML Health announced a first-of-its-kind partnership that gives clients the ability to manage their entire key opinion leader (KOL) identification and engagement operation from an integrated solution.
  • This partnership provides an answer to the increasingly complex challenges that the health industry faces when identifying and engaging with the most relevant KOLs at a global level.
  • The new solution has been created by linking VML Health’s digital KOL engagement platform and Definitive Healthcare’s comprehensive global KOL data available through the Monocl ExpertInsight platform.
  • "This will transform the way pharmaceutical companies interact with healthcare professionals,” says Claire Gillis, CEO of VML Health.

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Retrieved on: 
Freitag, März 15, 2024
Patient, Bone marrow failure, CSU, Clinical trial, Therapy, Definitive, CD117, FA

The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.

Key Points: 
  • The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.
  • The ongoing investigator initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab as a potential treatment for FA patients in bone marrow failure.
  • Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery.
  • “We’d like thank our collaborators at Stanford Medicine for their work evaluating briquilimab in this vulnerable patient population.”

ALX Resources Corp. Announces Option Earn-In Transaction and 2024 Winter Drilling Program for the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan

Retrieved on: 
Mittwoch, Februar 28, 2024
ALX, SGH, Definitive, Project

"ALX is pleased to welcome Trinex as a new partner in our Athabasca Basin uranium exploration," said Warren Stanyer, CEO and Chairman of ALX.

Key Points: 
  • "ALX is pleased to welcome Trinex as a new partner in our Athabasca Basin uranium exploration," said Warren Stanyer, CEO and Chairman of ALX.
  • "We look forward to forging a strong relationship between the two companies and to achieving drilling success at Gibbons Creek."
  • ALX and Trinex expect to negotiate a more comprehensive definitive option earn-in agreement (the "Definitive Agreement"), which will set out the definitive terms and conditions of the Transaction.
  • Six (6) targets have been selected for drill testing in the 2024 winter program, totaling approximately 1,200 metres of drilling.